Azithramycine

Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.

References related to locations published in J. Antimicrob. Chemother.

PMID	Journal	Published Date	Author	Title
10473232	J. Antimicrob. Chemother.	1999	Butler T et al.	Treatment of typhoid fever with azithromycin versus chloramphenicol in a randomized multicentre trial in India.
10511413	J. Antimicrob. Chemother.	1999	Jackson LA et al.	Safety and effect on anti-Chlamydia pneumoniae antibody titres of a 1 month course of daily azithromycin in adults with coronary artery disease.
11152432	J. Antimicrob. Chemother.	2001	Amsden GW and Gray CL	Serum and WBC pharmacokinetics of 1500 mg of azithromycin when given either as a single dose or over a 3 day period in healthy volunteers.
11679558	J. Antimicrob. Chemother.	2001	Contopoulos-Ioannidis DG et al.	Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections.
11751774	J. Antimicrob. Chemother.	2002	Firsov AA et al.	Comparative pharmacodynamics of azithromycin and roxithromycin with S. pyogenes and S. pneumoniae in a model that simulates in vitro pharmacokinetics in human tonsils.
11266420	J. Antimicrob. Chemother.	2001	Butler T et al.	In vitro effects of azithromycin on Salmonella typhi: early inhibition by concentrations less than the MIC and reduction of MIC by alkaline pH and small inocula.
11389120	J. Antimicrob. Chemother.	2001	Kurdowska A et al.	The effect of azithromycin and clarithromycin on ex vivo interleukin-8 (IL-8) release from whole blood and IL-8 production by human alveolar macrophages.
12096025	J. Antimicrob. Chemother.	2002	Butler T	Reduction of MIC of azithromycin for Salmonella typhi and Staphylococcus aureus in broth exposed to previous growth of Salmonella typhi.
12654747	J. Antimicrob. Chemother.	2003	Carryn S et al.	Activity of beta-lactams (ampicillin, meropenem), gentamicin, azithromycin and moxifloxacin against intracellular Listeria monocytogenes in a 24 h THP-1 human macrophage model.
12775677	J. Antimicrob. Chemother.	2003	Zhanel GG et al.	Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations.
12697643	J. Antimicrob. Chemother.	2003	Seral C et al.	Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus.
12461037	J. Antimicrob. Chemother.	2002	Chiu LM et al.	Pharmacokinetics of intravenous azithromycin and ceftriaxone when administered alone and concurrently to healthy volunteers.
10590283	J. Antimicrob. Chemother.	1999	Sendi PP et al.	Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy. The Swiss HIV Cohort Study.
11102409	J. Antimicrob. Chemother.	2000	Nagai K et al.	In vitro development of resistance to ceftriaxone, cefprozil and azithromycin in Streptococcus pneumoniae.
10702561	J. Antimicrob. Chemother.	2000	Giacometti A et al.	Anticryptosporidial activity of ranalexin, lasalocid and azithromycin alone and in combination in cell lines.
15163653	J. Antimicrob. Chemother.	2004	Wyrick PB and Knight ST	Pre-exposure of infected human endometrial epithelial cells to penicillin in vitro renders Chlamydia trachomatis refractory to azithromycin.
21059616	J. Antimicrob. Chemother.	2011	Muto C et al.	Pharmacokinetic-pharmacodynamic analysis of azithromycin extended release in Japanese patients with common respiratory tract infectious disease.
20022937	J. Antimicrob. Chemother.	2010	Biswas S et al.	Molecular mechanisms of Bartonella henselae resistance to azithromycin, pradofloxacin and enrofloxacin.
18252692	J. Antimicrob. Chemother.	2008	Lucchi M et al.	Pharmacokinetics of azithromycin in serum, bronchial washings, alveolar macrophages and lung tissue following a single oral dose of extended or immediate release formulations of azithromycin.
15845780	J. Antimicrob. Chemother.	2005	Blessing E et al.	A 6 week course of azithromycin treatment has no beneficial effect on atherosclerotic lesion development in apolipoprotein E-deficient mice chronically infected with Chlamydia pneumoniae.
16002421	J. Antimicrob. Chemother.	2005	Girard D et al.	Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.
17110394	J. Antimicrob. Chemother.	2007	Moon JE et al.	Effect of timing and duration of azithromycin therapy of leptospirosis in a hamster model.
16617063	J. Antimicrob. Chemother.	2006	Sevillano D et al.	Azithromycin iv pharmacodynamic parameters predicting Streptococcus pneumoniae killing in epithelial lining fluid versus serum: an in vitro pharmacodynamic simulation.
23152483	J. Antimicrob. Chemother.	2013	Pereira R et al.	Combination therapy for gonorrhoea: in vitro synergy testing.
23248239	J. Antimicrob. Chemother.	2013	Cory TJ et al.	Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.